Showing results (1-10 of 11) with videos related to
Sort By:
Pageof 2
Oncology|August 28, 2004
B-raf exon 15 mutations are common in primary melanoma resection specimens but not associated with clinical outcomeMartin Deichmann, Marianne Thome, Axel Benner, et al.Anti-Cancer Drugs|September 10, 2003
Inhibition of angiogenesis by non-toxic doses of temozolomideHjalmar Kurzen, Stefan Schmitt, Helmut Näher, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|December 18, 2009
Psoriatic arthritis: a reviewAnne Amherd-Hoekstra, Helmut Näher, Hanns-Martin Lorenz, et al.International Journal of Oncology|December 5, 2003
Somatic mitochondrial mutations in melanoma resection specimensMartin Deichmann, Birgit Kahle, Axel Benner, et al.Archives of Dermatological Research|January 5, 2005
Detection of reverse transcriptase activity in human melanoma cell lines and identification of a murine leukemia virus contaminantMartin Deichmann, Jon B Huder, Christian Kleist, et al.Transplantation|August 12, 2009
Extracorporeal photophoresis augments function of CD4+CD25+FoxP3+ regulatory T cells by triggering adenosine productionSabrina Schmitt, Theron S Johnson, Svetlana Karakhanova, et al.Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 16, 2010
New mutation in the CYLD gene within a family with Brooke-Spiegler syndromeIna M Scholz, Astrid Nümann, Ursula G Froster, et al.The Journal of Investigative Dermatology|October 16, 2004
Phenotypical and molecular profiling of the extraneuronal cholinergic system of the skinHjalmar Kurzen, Hans Berger, Claudia Jäger, et al.Melanoma Research|March 14, 2008
Management of primary and metastasized melanoma in Germany in the time period 1976-2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological SocietySilke S Schwager, Ulrike Leiter, Petra G Buettner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2010
Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trialAxel Hauschild, Michael Weichenthal, Knuth Rass, et al.Pageof 2